The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy

Veterinary Immunology and Immunopathology

Volumn 71, Issue 3-4, 1999, Pages 181-195

  Moreno, Javier ^a   Nieto, Javier ^a   Chamizo, Cristina ^a   González, Fernando ^b   Blanco, Fernando ^c   Barker, Douglas C ^d   Alvar, Jorge ^a  

^a WHO Collaborating Ctr Leishmaniasis   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Antigua Zona Industrial   (Spain)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Canine visceral leishmaniasis; Chemotherapy; Immune response; Leishmania infantum; Lymphoid subsets

Indexed keywords

AMPHOTERICIN B; CD4 ANTIGEN; FUNGIZONA; INTRALIPID; PARASITE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOG; FEMALE; HELPER CELL; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIA INFANTUM; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; MALE; MONONUCLEAR CELL; NONHUMAN; T LYMPHOCYTE; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; DOG DISEASES; DOGS; FEMALE; IMMUNE TOLERANCE; LEISHMANIASIS, VISCERAL; LEUKOCYTES, MONONUCLEAR; MALE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA;

ANIMALIA; CANIS FAMILIARIS; LEISHMANIA INFANTUM;

EID: 0032722008     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2427(99)00096-3     Document Type: Article

References (49)

1. Abranches P., Santos-Gomes G., Rachamim N., Campino L., Schnur L.F., Jaffe C.L. An experimental model for canine visceral leishmaniasis. Parasite Immunol. 13:1991;537-550.
2. Abranches P., Silva-Pereira M.C.D., Conceiçao-Silva F.M., Santos-Gomes G.M., Janz J.G. Canine leishmaniasis: pathological and ecological factors influencing transmission of infection. J. Parasitol. 77:1991;557-561.
3. Alvar J., Molina R., San Andrés M., Tesouro M., Nieto J., Vitutia M., González F., San Andrés M.D., Boggio J., Rodríguez F., Sáinz A., Escacena C. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann. Trop. Med. Parasitol. 88:1994;371-378.
4. Alvar J., Cañavate C., Gutiérrez-Solar B., Jiménez M., Laguna F., López-Vélez R., Molina R., Moreno J. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10:1997;298-319.
5. Ashford R.W. Leishmaniasis reservoirs and their significance in control. Clin. Dermatol. 14:1996;523-532.
6. Ashford D.A., David J.R., Freire M., David R., Sherlock I., Eulalio M.C., Sampaio D.P., Badaro R. Studies on control of viceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am. J. Trop. Med. Hyg. 59:1998;53-57.
7. Barral A., Carvalho E.M., Badaro R., Barral-Netto M. Suppression of lymphocyte proliferative responses by sera from patients with American visceral leishmaniasis. Am. J. Trop. Med. Hyg. 35:1986;735-742.
8. Bourdoiseau G., Bonnefont C., Magnol J.P., Saint-André I., Chabanne L. Lymphocyte subset abnormalities in canine leishmaniasis. Vet. Immunol. Immunopathol. 56:1997;345-351.
9. Bourdoiseau G., Bonnefont C., Hoareau E., Boehringer C., Stolle T., Chabanne L. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs. Vet. Immunol. Immunopathol. 59:1997;21-30.
10. Burns J.M., Shreffler W.G., Benson D.R., Ghalib H.W., Badaro R., Reed S.G. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc. Natl. Acad. Sci. USA. 90:1993;775-779.
11. Cabral M., O'Grady J., Alexander J. Demonstration of Leishmania specific cell mediated and humoral immunity in asymptomatic dogs. Parasite Immunol. 14:1992;531-539.
12. Caillot D., Casasnovas O., Solary E., Chavanet P., Bonnotte B., Reny G., Entezam F., López J., Bonnin A., Guy H. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J. Antimicrob. Chemother. 31:1993;161-169.
13. Carvalho E.M., Teixeira R.S., Johnson W.D. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect. Immun. 33:1981;498-502.
14. Carvalho E.M., Badaró R., Reed S.G., Jones T.C., Johnson W.D. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Invest. 76:1985;2066-2069.
15. Carvalho E.M., Bacellar O., Barral A., Badaro R., Johnson W.D. Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J. Clin. Invest. 83:1989;860-864.
16. Cenini P., Berhe N., Hailu A., McGinnes K., Frommel D. Mononuclear cell subpopulation and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J. Infect. Dis. 168:1993;986-993.
17. Cillari E., Liew F.Y., Lo Campo P., Milano S., Mansueto S., Salerno A. Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily. J. Immunol. 140:1988;2721-2726.
18. Cillari E., Vitale G., Arcoleo F., D'Agostino P., Mocciaro C., Gambino G., Malta R., Stassi G., Milano S., Mansueto S. In vivo and in vitro cytokine profiles and mononuclear cell subsets in sicilian patients with active visceral leishmaniasis. Cytokine. 7:1995;740-745.
19. Cobbold S., Metcalfe S. Monoclonal antibodies that define canine homologues of human CD antigens: Summary of the first international canine leukocyte antigen workshop (CLAW). Tissue Antigens. 43:1994;137-154.
20. Cobbold S., Holmes M., Willett B. The immunology of companion animals: reagents and therapeutic strategies with potential veterinary and human clinical applications. Immunol. Today. 15:1994;347-353.
21. Dietze R., Barros G.B., Texeira L., Harris J., Michelson K., Falqueto A., Corey R. Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil. Clin. Infect. Dis. 25:1997;1240-1242.
22. Dye C. The logic of visceral leishmaniasis control. Am. J. Trop. Med. Hyg. 55:1996;125-130.
23. Ghalib H.W., Piuvezam M.R., Skeiky Y.A.W., Siddig M., Hashim F.A., El-Hassan A.M., Russo D.M., Reed S.G. Interleukin-10 production correlates with pathology in human Leishmania donovani infection. J. Clin. Invest. 92:1993;324-329.
24. Gramiccia M., Gradoni L., Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann. Trop. Med. Parasitol. 86:1992;613-620.
25. Holaday B.J., Pompeu M.M.L., Jeronimo S., Texeira M.J., Sousa A.Q., Vasconcelos A.W., Pearson R.D., Abrams J.S., Locksley R.M. Potential role for interleukin-10 in the immunosuppression associated with kala-azar. J. Clin. Invest. 92:1993;2626-2632.
26. Kaye P.M., Curry A.J., Blackwell J.M. Differential production of Th1- and Th2 derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:1991;2763-2770.
27. Laguna, F., López-Vélez, R., Pulido, F., Salas, A., Torre-Cisneros, J., Torres, E., Medrano., Sanz, J., Picó, G., Gómez-Rodrigo, J., Pasquau, J., Alvar, J., Spanish HIV-Leishmania Study Group., 1999. Treatment of visceral leishmaniasis in human immunodeficiency virus infected patients. A randomized trial comparing amphotericin B to meglumine antimoniate. AIDS, (in press).
28. Lamothe J. Essai de traitement de la leishmaniose canine par l'amphotéricine B (39 cas). Prat. Méd. Chir. Anim. Comp. 32:1997;133-141.
29. Liew F.Y., O'Donnell C.A. Immunology of leishmaniasis. Adv. Parasitol. 32:1993;161-259.
30. Mancianti F., Gramiccia M., Gradoni L., Pieri S. Studies on canine leishmaniasis control 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment. Trans. R. Soc. Trop. Med. Hyg. 82:1988;566-567.
31. Manson-Bahr P.E.C. Immunity in kala-azar. Trans. R. Soc. Trop. Med. Hyg. 55:1961;550-555.
32. Murray H.W., Stern J.J., Welte K., Rubin B.Y., Carreiro S.M., Nathan C.F. Experimental visceral leishmaniasis: production of Interleukin-2 and interferon-γ, tissue immune reaction and response to treatment with interleukin-2 and interferon-γ J. Immunol. 138:1987;2290-2297.
33. Murray H.W., Oca M.J., Granger A.M., Schreiber R.D. Requirement of T cells and effects of lymphokines in successful chemotherapy for an intracellular infection. J. Clin. Invest. 83:1989;1253-1257.
34. Nabors G.S., Farrel J.P. Successful chemotherapy in experimental leishmaniasis is influenced by the polarity of the T cell response before treatment. J. Infect. Dis. 173:1996;979-986.
35. Oliva G., Gradoni L., Ciamarella P., De Luna R., Cortese L., Orsini S., Davidson R.N., Persechino A. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J. Antimicrob. Chemother. 36:1995;1013-1019.
36. Pinelli E., Rutten V.P.M.G., Bruysters M., Moore P.F., Ruitenberg E.J. Compensation for decreased expression of B7 molecules on Leishmania infantum-infected canine macrophages results in restoration of parasite-specific T-cell proliferation and gamma interferon production. Infect. Immun. 67:1999;237-243.
37. Pinelli E., Killick-Kendrick R., Wagenaar J., Bernardina W., Del Real G., Ruitenberg J. Cellular and humoral immune response in dogs experimentally and naturally infected with Leishmania infantum. Infect. Immun. 62:1994;229-235.
38. Raziuddin S., Telmasani A.W., El-Awad M.E., Al-Amari O., Al-Janadi M. γδ T cells and the immune response in visceral leishmaniasis. Eur. J. Immunol. 22:1992;1143-1148.
39. Reiner N.E., Ng W., Ma T., Mcmaster W.R. Kinetics of γ-interferon binding and induction of major histocompability complex class II mRNA in Leishmania-infected macrophages. Proc. Natl. Acad. Sci. USA. 85:1988;4330-4334.
40. Rohtagi A., Agarwal S.K., Bose M., Chattopadhya D., Saha K. Blood, bone marrow and splenic lymphocyte subset profiles in Indian visceral leishmaniasis. Trans. Roy. Soc. Trop. Med. Hyg. 90:1996;431-434.
41. Russo D.M., Armitage R.J., Barral-Netto M., Barral A., Grabstein K.H., Reed S.G. Antigen-reactive γδ T cells in human leishmaniasis. J. Immunol. 151:1993;3712-3718.
42. Sacks D.L., Lal S.L., Shrivastava S.N., Blackwell J., Neva F.A. An analysis of T cell responsiveness in Indian kala-azar. J. Immunol. 138:1987;908-913.
43. Saha B., Das G., Vohra H., Ganguly N.K., Mishra G.C. Macrophage-T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell mediated immunity. Eur. J. Immunol. 25:1995;2492-2498.
44. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model I. Induction of protective immunity with a soluble extract of promastigotes. J. Immunol. 139:1987;221-227.
45. Stern J.J., Oca M.J., Rubin B.Y., Anderson S., Murray H.W. Role of L3T4+ and LYT-2+ cells in experimental visceral leishmaniasis. J. Immunol. 140:1988;3971-3977.
46. Tesh R.B. Control of zoonotic visceral leishmaniasis: is it time to change strategies? Am J. Trop. Med. Hyg. 52:1995;287-292.
47. Tumang M.C.T., Keogh C., Moldawer L.L., Helfgott D.C., Teitelbaum R., Hariprashad J. Role and effect of TNF-α in experimental visceral leishmaniasis. J. Immunol. 153:1994;768-775.
48. World Health Organization, 1990. Control of the leishmaniases. Technical report series 793. WHO, Geneva, Switzerland.
49. Zwingenberger K., Harms G., Pedrosa C., Omena S., Sendkamp B., Neiger S. Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous IL-4 over IFN-γ production. Clin. Immunol. Immunopathol. 57:1990;242-249.